



Keeping in line with BD's commitment to bringing new technologies and innovation to improve human healthcare, the Company made a strategic acquisition in fiscal year 2007. In December of 2006, BD acquired TriPath Imaging, Inc. BD's TriPath platform develops, manufactures, markets and sells innovative solutions to improve the clinical management of cancer. This strategic acquisition aligns innovative new technologies with BD's existing business strategies and is a natural complement to ongoing internal research programs in our BD Diagnostics and BD Biosciences segments. No other major changes took place in operations in fiscal year 2007.

BD's Success Model

- Early identification of underappreciated or emerging global healthcare needs
- Application of technology (internal, adapted, adopted, licensed, etc.)
- Manufacturing excellence (used to make the product available and affordable)
- Outstanding service and support (through our global sales organization)
- Surrounded by the passion of our associates

Segments and Major Products

Three segments represent BD in worldwide markets: BD Medical, BD Diagnostics and BD Biosciences.

BD Medical

BD Medical is among the world's leading suppliers of medical devices. BD built the first-ever manufacturing facility in the U.S. to produce syringes and needles in 1906 and has been the leading innovator in injection- and infusion-based drug delivery ever since.

BD Diagnostics

BD Diagnostics is a leading provider of products for the safe collection and transport of diagnostic specimens and instruments for quick, accurate analysis across a broad range of infectious diseases, including the growing problem of healthcare-associated infections (HAIs). The segment is composed of two operating units: Preanalytical Systems, a world leader in sample collection, and Diagnostic Systems, a leader in microbiology testing products and molecular assays.

BD Biosciences

BD Biosciences is one of the world's leading businesses bringing innovative tools to life scientists, clinical researchers and clinicians. Our customers are involved in basic research, drug and vaccine discovery and development, biopharmaceutical production, clinical trials, diagnostic testing and disease management.



Report Parameters

Unless otherwise noted, this report covers financial data for fiscal year 2007 (October 1, 2006 to September 30, 2007) and encompasses the entire Company in all regions of the world. However, this report does not cover joint ventures or strategic alliances. Data presented in this report are from BD operations worldwide unless otherwise noted. Environmental data are from manufacturing, research and development, distribution, and major administrative facilities covering the calendar year 2006. Safety and health data covers fiscal year 2006.

Accuracy and Reliability of Report

BD prepared this report to address the Company's policies and practices with regard to health and safety, environmental, social and economic issues.

The BD Corporate Environment and Safety Department has processes to review the data included in this report. The department is responsible for audits of BD facilities worldwide and believes that information concerning those plants and their operations is accurate. In addition, internal subject matter experts who provided health and safety, environmental, social, economic and governance information have reviewed this report.

Access to Additional Information

Additional information about BD may be obtained through:

- [BD Website](#)
- [BD 2007 Annual Report](#)

BD Corporate Safety and Environmental Department at bdse@bd.com